Treatment Patterns and Survival in Older Patients with FIGO Stage IIB–IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinomas
- 1Department of Obstetrics and Gynecology, Beijing Chaoyang Hospital, Capital Medical University, No. 8 Gongti South Road, Chaoyang District, Beijing 100020, China
Abstract
Background: Older adults with epithelial ovarian cancer (EOC) are underrepresented in prospective studies, and treatment selection is influenced by frailty, comorbidity, disease burden, and clinician assessment. We evaluated treatment patterns, operative outcomes, and survival associations in a single-center cohort of patients aged 70 years or older with FIGO stage IIB–IV EOC-spectrum malignancies. Methods: We screened 122 patients treated between January 2010 and December 2023 and included 97 patients after exclusions. The primary outcomes were progression-free survival (PFS) and overall survival (OS). PFS excluded seven patients recorded as receiving no treatment, whereas OS included all 97 patients. Kaplan–Meier methods were used to estimate PFS and OS, and overall log-rank tests were used to compare survival across age groups. Exploratory Cox proportional-hazards models included age, FIGO stage, and diagnosis era; post-baseline treatment completion and maintenance therapies were not included as fixed covariates because of potential guarantee-time bias and incomplete exposure dates. Results: The cohort comprised 44 patients aged 70–74 years, 38 aged 75–79 years, and 15 aged 80 years or older. Recorded treatment groups were primary debulking surgery (PDS; n = 46), NACT followed by recorded interval debulking surgery (NACT + IDS; n = 22), chemotherapy alone (n = 22), and no treatment (n = 7). Among the 90 patients in the PFS population, 61 experienced an event; among all 97 patients, 36 died. Median PFS was 22.0 months (95% CI, 16.0–24.0) and median OS was 51.5 months (95% CI, 38.0–not reached). Age-group log-rank p values were 0.684 for PFS and 0.248 for OS. The baseline Cox models were exploratory and showed no statistically significant association between age and PFS or OS after adjustment for FIGO stage and diagnosis era. Conclusions: This retrospective cohort does not establish that age, surgery, treatment completion, or maintenance therapy causes a survival difference. Survival estimates among patients aged 80 years or older were imprecise. Treatment comparisons should be interpreted as selected-cohort associations, and prospective studies incorporating validated geriatric, comorbidity, molecular, and time-dependent treatment information are needed.
Related
- Successful Treatment of an Atypical Mycobacterial Exit Site Infection in a Patient on Peritoneal Dialysis: A Case Report
- Diagnosis and minimally invasive surgical treatment of peritoneal dialysis-associated pleuroperitoneal fistula: A case report and literature review.
- Treatment Approach to Disseminated Peritoneal Leiomyomatosis in A Patient Desiring Future Fertility: A Case Report
- Camrelizumab plus famitinib as first-line treatment for locally advanced or metastatic pulmonary sarcomatoid carcinomas (CAPSTONE): a multi-center, single-arm, phase 2 trial
- Distinct patterns of insulin-like growth factor binding protein (IGFBP)-2 and IGFBP-3 expression in oxidant exposed lung epithelial cells
BibTeX
@article{zhang2026treatment,
title = {{Treatment Patterns and Survival in Older Patients with FIGO Stage IIB–IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinomas}},
author = {Tingting Zhang and Bing Liang and Cuiqin Sang and Zhengchen Guo and Weihua Li and Shuiqing Xu and Hua Li},
journal = {Journal of Clinical Medicine},
year = {2026},
month = oct,
doi = {10.3390/jcm15207845},
url = {https://www.mdpi.com/2077-0383/15/20/7845},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Treatment Patterns and Survival in Older Patients with FIGO Stage IIB–IV Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinomas
AU - Tingting Zhang
AU - Bing Liang
AU - Cuiqin Sang
AU - Zhengchen Guo
AU - Weihua Li
AU - Shuiqing Xu
AU - Hua Li
PY - 2026
DA - 2026/10/12
JO - Journal of Clinical Medicine
DO - 10.3390/jcm15207845
UR - https://www.mdpi.com/2077-0383/15/20/7845
AB - Background: Older adults with epithelial ovarian cancer (EOC) are underrepresented in prospective studies, and treatment selection is influenced by frailty, comorbidity, disease burden, and clinician assessment. We evaluated treatment patterns, operative outcomes, and survival associations in a single-center cohort of patients aged 70 years or older with FIGO stage IIB–IV EOC-spectrum malignancies. Methods: We screened 122 patients treated between January 2010 and December 2023 and included 97 patients after exclusions. The primary outcomes were progression-free survival (PFS) and overall survival (OS). PFS excluded seven patients recorded as receiving no treatment, whereas OS included all 97 patients. Kaplan–Meier methods were used to estimate PFS and OS, and overall log-rank tests were used to compare survival across age groups. Exploratory Cox proportional-hazards models included age, FIGO stage, and diagnosis era; post-baseline treatment completion and maintenance therapies were not included as fixed covariates because of potential guarantee-time bias and incomplete exposure dates. Results: The cohort comprised 44 patients aged 70–74 years, 38 aged 75–79 years, and 15 aged 80 years or older. Recorded treatment groups were primary debulking surgery (PDS; n = 46), NACT followed by recorded interval debulking surgery (NACT + IDS; n = 22), chemotherapy alone (n = 22), and no treatment (n = 7). Among the 90 patients in the PFS population, 61 experienced an event; among all 97 patients, 36 died. Median PFS was 22.0 months (95% CI, 16.0–24.0) and median OS was 51.5 months (95% CI, 38.0–not reached). Age-group log-rank p values were 0.684 for PFS and 0.248 for OS. The baseline Cox models were exploratory and showed no statistically significant association between age and PFS or OS after adjustment for FIGO stage and diagnosis era. Conclusions: This retrospective cohort does not establish that age, surgery, treatment completion, or maintenance therapy causes a survival difference. Survival estimates among patients aged 80 years or older were imprecise. Treatment comparisons should be interpreted as selected-cohort associations, and prospective studies incorporating validated geriatric, comorbidity, molecular, and time-dependent treatment information are needed.
SN - 2077-0383
ER -